Author:
Shacham Shmueli Einat,Geva Ravit,Yarom Nirit,Hubert Ayala,Keynan Rita,Kedem Tal H.,Eini Meir,Tamarkin Dov,Shirvan Mitchell
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Chanprapaph K, Vachiramon V, Rattanakaemakorn P (2014) Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract 2014:734249.
https://doi.org/10.1155/2014/734249
2. Erbitux (cetuximab) Prescribing Information. Indianapolis, IN: Eli Lilly and Company; October 2016
3. Vectibix (panitumumab) Prescribing Information. 2015. Thousand Oaks, CA: Amgen, Inc; March 2015
4. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG (2014) Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 53(3):376–384.
https://doi.org/10.1111/ijd.12205
5. Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21(11 Suppl 5):34–36
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献